The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
about
Medical management of brain tumors and the sequelae of treatment.What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data SourcesLong-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDsProcalcitionin as a diagnostic marker to distinguish upper and lower gastrointestinal perforation.Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients.Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.Integrated safety in tocilizumab clinical trials.Assessment of risk for recurrent diverticulitis: a proposal of risk score for complicated recurrenceIncreased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: a longitudinal population-based studyFactors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis.Life-Threatening Gastrointestinal Mucosal Necrosis during Methotrexate Treatment for Rheumatoid Arthritis.Successful Use of Tocilizumab in a Patient with Coexisting Rheumatoid Arthritis and Ulcerative ColitisLower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.Increased diverticular complications with nonsteriodal anti-inflammatory drugs and other medications: a systematic review and meta-analysis.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Pre-operative anesthetic assessment of patients with rheumatoid arthritis.Adverse reactions to biologic agents and their medical management.Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib.Multiple transverse colonic perforations associated with slow-release nonsteroidal anti-inflammatory drugs and corticosteroids: a case report.Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritisThe risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.Percutaneous embolization of persistent low-output enterocutaneous fistulas.Selective inhibition of CDK7 ameliorates experimental arthritis in mice.
P2860
Q26992174-B68D8BC1-BEF0-48E5-9B15-8BB9693B4B06Q28074148-D752C899-412F-4C29-8DA1-4DA0212700E8Q31137082-A06CC9ED-D5D0-4C64-BEF6-93FCF3B020D5Q31158500-CF289F22-97CA-45DD-B0D1-F428C0AB0EEFQ33731689-4476C5D5-E35F-472D-B908-644D6C9B1A50Q33843450-65B4DF08-A485-44AA-A4E5-5162A074AC64Q34054817-A65097B1-1A26-4AE3-B5A6-5396F5596D0AQ34818636-1D6B09AE-A1D2-410B-BD3D-28055711A7FCQ35840716-F484CE74-AF20-4BF0-8305-969362A0F3DCQ36009424-F7AC8F09-067D-4106-89DA-F88B9CAF1D0BQ36074289-E1F36E16-98DE-4092-9FF1-1C2F454E27DDQ36428779-0D105C94-2F38-4B04-ABCB-0B64E22B7FA0Q37350778-00E07EA1-FBF0-4E1C-8299-3EB009BD7D91Q37366588-7D3F37D1-4698-4AFF-A582-3C0E351F8DBAQ37915351-1E31EEAC-75CE-476C-97AA-EEB0C0940BBCQ38169787-015FA4AC-0A99-4B13-B029-19876ADBB362Q38176745-921A37A2-2955-477B-8E68-B73506F021C4Q38233119-1CE4EE61-7C03-4CF8-84CD-A14E5AEA9E55Q38238948-7D8B9280-85CF-4BA7-989B-7A7AB7BECF48Q38604390-E63A173F-F0EA-4A83-A7AC-C0F26A878D2CQ39223703-28DCF1E7-258B-49B0-92EE-06919F4FA9A0Q39744551-6F9BF204-BB0B-4602-86AD-4CBA528E2E94Q41933635-6E0755BC-F567-48C7-B6CE-D959AAEFBBDAQ51019088-5362B77B-539C-4579-9986-2C17A2E6E57DQ53163816-C0AFBD61-F954-46F2-9CDC-584D97367C74Q54327713-488A0D8C-F73D-4438-88AD-852AACC3A72F
P2860
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
@ast
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
@en
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
@nl
type
label
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
@ast
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
@en
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
@nl
prefLabel
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
@ast
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
@en
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
@nl
P2093
P2860
P356
P1476
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
@en
P2093
Claire Spettell
Elizabeth Delzell
Fenglong Xie
Jeffrey R Curtis
Joaquim Fernandes
Raechele M McMahan
P2860
P304
P356
10.1002/ART.30107
P577
2011-02-01T00:00:00Z